Establishment of an Advanced In Vitro Model for Pseudoexfoliation Syndrome and Glaucoma

建立假性剥脱综合征和青光眼的高级体外模型

阅读:1

Abstract

PURPOSE: Pseudoexfoliation (PEX) glaucoma is caused by progressive accumulation of abnormal fibrillar aggregates in aqueous humor outflow tissues. The current lack of effective models for PEX research, replicating the key feature of PEX material production, represents a critical gap in understanding the molecular pathomechanisms and identifying specific therapeutic targets. We have developed an advanced in vitro model using stromal fibroblasts from iridectomy specimens of PEX glaucoma patients with an appropriate genetic background. METHODS: Peripheral iridectomy specimens were obtained from patients with PEX glaucoma (n = 35) during routine trabeculectomy. Stromal fibroblasts were enriched from heterogenous cell cultures. Extracellular matrix formation was stimulated and modulated in two- and three-dimensional (3D) spheroid cultures by TGF-β1, Ficoll 400, all-trans-retinoic acid (ATRA), and curcumin. Cell cultures were analyzed by immunocytochemistry, transmission electron microscopy and qPCR. Immortalized cell lines (n = 4) were generated by SV40 large T-antigen transfection. RESULTS: Fibroblasts carrying the high-risk haplotype of LOXL1 (lysyl oxidase-like 1) expressed PEX-relevant matrix components and assembled an elastic fibrillar network, particularly upon treatment with TGF-β1 and the macromolecular crowding agent Ficoll 400. In 3D spheroid cultures, the presence of typical fibrillar PEX aggregates could be demonstrated by electron microscopy. Matrix production could be effectively suppressed by ATRA and curcumin. Similar to primary cells, immortalized cell lines formed 3D spheroids and expressed PEX-relevant matrix components including typical fibrillar aggregates. CONCLUSIONS: This advanced in vitro model, which recapitulates the hallmark of PEX syndrome/glaucoma, may provide a useful, easy-to-handle platform for studying disease mechanisms, assessing the impact of genetic and external factors, and exploring effects of targeted therapies for PEX-associated fibrosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。